How much weight did people lose on eloralintide?

In the 48-week phase 2 trial, average loss ranged from about 9.5% to 20.1% depending on dose, versus 0.4% on placebo.

When will eloralintide be available?

Phase 3 trials began in late 2025 and early 2026, with primary completion expected around 2028. It is not approved.

What are eloralintide side effects?

Nausea and fatigue were most common in phase 2, more often at higher doses.

Is eloralintide a GLP-1?

No. It targets amylin receptors. It may be studied alongside GLP-1 drugs, but it is a separate mechanism.

Eloralintide: Lilly's Investigational Amylin Agonist

Eloralintide explained: an investigational amylin-receptor agonist for obesity, early trial themes, and how it differs from GLP-1 drugs. Not medical advice.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Eloralintide is an Eli Lilly amylin-receptor agonist in clinical development for weight management. Amylin is a hormone co-released with insulin that slows gastric emptying and signals fullness — a different pathway from GLP-1. Phase 2 results reported meaningful average weight loss with gastrointestinal side effects as the main tolerability theme. It is investigational, not approved. The closest compound with reports on this site is cagrilintide, another amylin analogue. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Phase 2 results

48-week phase 2 trial in 263 adults with obesity or overweight and no type 2 diabetes, published in The Lancet (November 2025). Efficacy estimand; last reviewed October 15, 2026.

Arm	Average weight change at 48 weeks
Lowest dose arm	About 9.5%
Middle dose arms	About 12–18%
Highest dose arm	About 20.1%
Placebo	About 0.4%

Side effects reported

Nausea and fatigue were the most common adverse events, and both rose at higher doses in some arms (nausea up to about 64% in one arm vs 14% on placebo; fatigue up to about 46% vs 12%). Slower dose escalation appeared to reduce GI effects in some arms. Phase 2 trials are small, so rates may shift in larger studies.

Where it is in development

Lilly started the ENLIGHTEN phase 3 programme between December 2025 and February 2026, including trials in people with and without type 2 diabetes and one adding eloralintide to an existing weekly incretin. Primary results are not expected before 2028. Anything sold online as eloralintide now is not the investigational product and has no quality assurance.

Amylin vs GLP-1 drugs

Amylin agonists act on fullness and stomach emptying through different receptors from GLP-1 drugs, so companies are testing them alone and in combination. Novo Nordisk's CagriSema pairs the amylin analogue cagrilintide with semaglutide. Compare eloralintide vs retatrutide and approved options at GLP-1 medications.

What users report here

Anonymous accounts are collected on the Cagrilintide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.

More confessions from the archive

Community Q&A

How much weight did people lose on eloralintide?: In the 48-week phase 2 trial, average loss ranged from about 9.5% to 20.1% depending on dose, versus 0.4% on placebo.
When will eloralintide be available?: Phase 3 trials began in late 2025 and early 2026, with primary completion expected around 2028. It is not approved.
What are eloralintide side effects?: Nausea and fatigue were most common in phase 2, more often at higher doses.
Is eloralintide a GLP-1?: No. It targets amylin receptors. It may be studied alongside GLP-1 drugs, but it is a separate mechanism.
Is eloralintide approved?: No. It is in clinical trials.
Does this page give dosing advice?: Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.